Please login to the form below

Not currently logged in
Email:
Password:

short bowel syndrome

This page shows the latest short bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

Pfizer buys dwarfism drug company Therachon for $810m

Pfizer buys dwarfism drug company Therachon for $810m

Will rival BioMarin pipeline drug. Pfizer is spending $340m to acquire Therachon, a European biotech with a drug in trials for achondroplasia, a form of short-limbed dwarfism. ... Therachon has another asset in development, a GLP-2 analogue called

Latest news

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    The recent EMA approval of the subcutaneous formulation of its Inflammatory Bowel Disease (IBD) drug Entyvio was another milestone, as well as an important boost for patients. ... Projects that address gut inflammation beyond IBD are focused on coeliac

  • A rare talent A rare talent

    This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel

  • Pharma deals during January 2015 Pharma deals during January 2015

    Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and

  • Pharma deals during March 2013 Pharma deals during March 2013

    NPS Pharmaceuticals acquired back from Takeda the rights outside North America to teduglutide, an orphan drug for adult short bowel syndrome and rPTH 1-84, which is approved for osteoporosis in ... 160. † Takeda Pharmaceuticals/ NPS Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics